SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-18-015639
Filing Date
2018-11-13
Accepted
2018-11-13 06:31:20
Documents
59
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 443622
2 ex31-1.htm EX-31.1 15757
3 ex32-1.htm EX-32.1 7617
4 coverpage-logo_001.jpg GRAPHIC 38214
  Complete submission text file 0001493152-18-015639.txt   3277261

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE endv-20180930.xml EX-101.INS 532276
6 XBRL SCHEMA FILE endv-20180930.xsd EX-101.SCH 42822
7 XBRL CALCULATION FILE endv-20180930_cal.xml EX-101.CAL 52532
8 XBRL DEFINITION FILE endv-20180930_def.xml EX-101.DEF 168850
9 XBRL LABEL FILE endv-20180930_lab.xml EX-101.LAB 313045
10 XBRL PRESENTATION FILE endv-20180930_pre.xml EX-101.PRE 250144
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 181174884
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1